At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Bevacizumab +2 moredrug
Likely dose
Bevacizumab 10mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Gemcitabine/Carboplatin/Bevacizumab in Platinum Sensitive Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.
Ohio State University Comprehensive Cancer Center·interventional·Posted Dec 21, 2005·Updated Apr 30, 2015
In Brief
A Phase 2 clinical trial evaluating Bevacizumab, Gemcitabine, and 1 other intervention for Ovarian Cancer and 2 related conditions. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The purpose of this study is to test the effectiveness, safety and tolerability of the drug combination: gemcitabine, carboplatin and bevacizumab in patients that have been diagnosed with platinum sensitive recurrent ovarian cancer, fallopian tube or primary peritoneal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
CountriesUnited States
CollaboratorsGenentech, Inc., Eli Lilly and Company
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedDec 2005
Primary CompletionSep 2013
Study CompletionDec 2013
TodayJul 2026
First PostedDec 21, 2005
Enrollment StartNov 1, 2005
Primary CompletionSep 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7.8 yearsPosted 20.5 years ago
Interventions
Bevacizumabdrug
Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
Gemcitabinedrug
A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
Carboplatindrug